Abiopharma

OncoSec Medical Incorporated is a biopharmaceutical company developing its proprietary DNA-based intratumoral cancer immunotherapy technology, ImmunoPulse. OncoSec Medicals core technology is designed to enhance the local delivery and uptake of DNA IL-12 and other DNA-based agents that target tumor-induced immune subversion pathways. ImmunoPulse is a therapeutic approach that utilizes an electroporation delivery device in combination with DNA-encoded immune target modulators to treat cancer. Clinical studies of ImmunoPulse have demonstrated that the therapy is well-tolerated and preliminary evidence of anti-tumor activity has been observed, including the potential to initiate an immune response without the toxicities associated with systemic treatments. OncoSec Medicals lead program is evaluating ImmunoPulse for the treatment of metastatic melanoma. A Phase 2b study is in development to evaluate ImmunoPulse in combination with a checkpoint inhibitor, called anti-PD1 (pembrolizumab), for the treatment of metastatic melanoma and is being conducted in collaboration with several prominent academic medical centers. The company is also focused on identifying and developing new DNA-encoded proteins that target key pathways of tumor-induced immune subversion, investigating additional tumor indications, and evaluating other combination-based immunotherapy approaches. For more information, please visit www.oncosec.com.

Additional info from OTC:
OncoSec Medical Incorporated is a biopharmaceutical company developing its proprietary DNA-based intratumoral cancer immunotherapy technology, ImmunoPulse. OncoSec Medicals core technology is designed to enhance the local delivery and uptake of DNA IL-12 and other DNA-based agents that target tumor-induced immune subversion pathways. ImmunoPulse is a therapeutic approach that utilizes an electroporation delivery device in combination with DNA-encoded immune target modulators to treat cancer. Clinical studies of ImmunoPulse have demonstrated that the therapy is well-tolerated and preliminary evidence of anti-tumor activity has been observed, including the potential to initiate an immune response without the toxicities associated with systemic treatments. OncoSec Medicals lead program is evaluating ImmunoPulse for the treatment of metastatic melanoma. A Phase 2b study is in development to evaluate ImmunoPulse in combination with a checkpoint inhibitor, called anti-PD1 (pembrolizumab), for the treatment of metastatic melanoma and is being conducted in collaboration with several prominent academic medical centers. The company is also focused on identifying and developing new DNA-encoded proteins that target key pathways of tumor-induced immune subversion, investigating additional tumor indications, and evaluating other combination-based immunotherapy approaches. For more information, please visit www.oncosec.com.